7 unknown, 2 not yet recruiting, 1 completed, 1 terminated. 4 Not applicable, 4 Phase 2, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Unknown 2, Completed 1, Not yet recruiting 1 |
| Phase 2 | 4 | Unknown 3, Terminated 1 |
| Phase 1 | 2 | Terminated 1, Unknown 1 |
| Early Phase 1 | 1 | Unknown 1 |
Follow Primary Hepatocellular Carcinoma: new trials by email Literature Review of Primary Hepatocellular Carcinoma trials Research Report on Primary Hepatocellular Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer complex behavioral intervention - Primary Hepatocellular Carcinoma, Unresectable Liver Cancer | Not applicable | Not yet recruiting | Eastern Hepatobiliary Surgery Hospital | 193 | 2026-01-01 | 2026-01-13 |
| 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness Observational study of 29 - gene - defined HCC subtypes and immunotherapy responsiveness correlation - Primary Hepatocellular Carcinoma | Not yet recruiting | Junjie Xu | 350 | 2025-08-01 | 2025-08-03 | |
| Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), camrelizumab for Injection - Primary Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | CNBG-Virogin Biotech (Shanghai) Ltd. | 36 | 2023-11-30 | 2023-11-15 |
| H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis Recombinant human adenovirus type 5 + TACE - Primary Hepatocellular Carcinoma, Portal Vein Thrombosis | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 38 | 2023-06-01 | 2023-05-24 |
| Clinical Study of MAK Immune Cells in the Treatment of PHC Mixed-activated Killer Immune Cells - Primary Hepatocellular Carcinoma | Not applicable | Unknown | Zhongnan Hospital | 12 | 2021-01-01 | 2022-02-16 |
| Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma SBRT, IMRT, Hepatectomy - Primary Hepatocellular Carcinoma | Not applicable | Unknown | The Third Xiangya Hospital of Central South University | 200 | 2018-10-10 | 2019-01-23 |
| Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC c-Met/PD-L1 CAR-T cell injection - Primary Hepatocellular Carcinoma | Early Phase 1 | Unknown | The Second Hospital of Nanjing Medical University | 50 | 2018-10-01 | 2018-09-18 |
| Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients TACE, Arsenic trioxide - Primary Hepatocellular Carcinoma | Phase 2 | Unknown | Hunan Provincial People's Hospital | 190 | 2016-11-01 | 2017-02-23 |
| Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy DC-TC+GM-CSF - Primary Hepatocellular Carcinoma | Not applicable | Completed | Shanghai AbelZeta Ltd. | 8 | 2012-12-01 | 2013-12-23 |
| Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media Primary Hepatocellular Carcinoma | Unknown | Li Chen | 50 | 2012-03-01 | 2012-04-02 | |
| Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma CT-011 - Primary Hepatocellular Carcinoma | Phase 1 / Phase 2 | Terminated | CureTech Ltd | 2 | 2009-10-01 | 2012-10-23 |
Carcinoma, Hepatocellular (11)
Adenocarcinoma (11) · Carcinoma (11) · Digestive System Diseases (11) · Digestive System Neoplasms (11) · Liver Diseases (11) · Liver Neoplasms (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Neoplasms by Site (11) · Neoplasms, Glandular and Epithelial (11)
Arsenic Trioxide (1) · Hepatectomy (1) · Injections (1) · camrelizumab (1) · pidilizumab (1)
CNBG-Virogin Biotech (Shanghai) Ltd. (1) · CureTech Ltd (1) · Eastern Hepatobiliary Surgery Hospital (1) · Hunan Provincial People's Hospital (1) · Junjie Xu (1) · Li Chen (1) · Shanghai AbelZeta Ltd. (1) · The Second Hospital of Nanjing Medical University (1) · The Third Xiangya Hospital of Central South University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Zhongnan Hospital (1)
China (7) · Israel (1)
Chengwei Chen (1) · Gao-Jun Teng, MD (1) · Guozhong Ji, archiater (1) · Hua Xiang, Dr. (1) · Qifa Ye, MD, PHD (1) · Tingbo Tingbo, MD. PhD. (1) · Tongguo Si (1) · Yaron Ilan, MD (1)